THE US Food and Drug
Administration has approved
Tafinlar (dabrafenib) and Mekinist
(trametinib), for the treatment
of patients with non-resectable
melanoma.
Tafinlar is a BRAF inhibitor and
Mekinist is a MEK inhibitor, with
both approvals for patients with
particular gene mutations.
The approval comes along with a
genetic test called the THxID BRAF
test, which detects the V600E or
V600K mutation in the BRAF gene.
Melanoma is the leading cause of
death from skin disease, with about
half of melanomas arising in the
skin having a BRAF gene mutation.The above article was sent to subscribers in Pharmacy Daily's issue from 07 Jun 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 07 Jun 13
NSW pharmacists will be able to treat common skin conditions under a new clinical trial from 12 Jul, announced the state’s Health Minister Ryan Park today.
THE Council of Pharmacy Schools of Australia and New Zealand (CPS) representatives will provide insights into studying contemporary pharmacy degrees at the Pharmacy Careers Summit (PCS24) next week.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.